The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

The diabetic neuropathy market is poised for growth driven by clinical evidence, patient-centric care, digital health models, and innovative pharmacologic options. Key opportunities include enhancing ...

Axsome Therapeutics AXSM announced the initiation of the phase III study called FORWARD with the dosing of the first patient, ...

Which of the statements about the recent guideline for evaluating and managing peripheral nervous system manifestations of Sjögren disease are correct?

Following out-of-hospital cardiac arrest, targeting mild hypercapnia vs normocapnia during IMV was linked to less right ventricular dysfunction.